Login to Your Account

Talon Rescue: Spectrum Gains Marqibo in Bargain Acquisition

By Jennifer Boggs
Managing Editor

Wednesday, July 17, 2013

In a deal reminiscent of last year's acquisition of struggling Allos Therapeutics Inc., Spectrum Pharmaceuticals Inc. nabbed cash-strapped Talon Therapeutics Inc. for a mere $11.3 million in cash up front, gaining rights to Marqibo, a nanoparticle encapsulation version of microtubule inhibitor vincristine, which gained approval last year in a subset of acute lymphoblastic leukemia (ALL) patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription